Archive for the ‘british j of cancer’ Category
Another retraction for Pfizer’s experimental cancer treatment figitumumab
Last month, we brought you news that Pfizer had retracted a paper in the Journal of Clinical Oncology
purporting to show a benefit of their experimental drug for lung cancer figitumumab after discovering that its clinical lead on the project had done analyses improperly.
There’s been another retraction, of a related paper, in the British Journal of Cancer, “Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab.” Here’s the notice: Read the rest of this entry »
Five retractions for cancer research team for manipulated figures
The International Journal of Cancer, a Wiley title, has retracted a pair of articles from a group at UT Southwestern Medical Center in Dallas, for image manipulation.
The papers, from the lab of Adi Gazdar, the W. Ray Wallace Distinguished Chair in Molecular Oncology Research who is known for his massive collection of human cancer cells, were published in 2005.
The first was titled “Aberrant methylation of Reprimo in human malignancies.” According to the retraction notice: Read the rest of this entry »
